Application of pharmacokinetics modelling to predict human exposure of a cationic liposomal subunit antigen vaccine system by Badhan, Raj K.S. et al.
pharmaceutics
Article
Application of Pharmacokinetics Modelling to Predict
Human Exposure of a Cationic Liposomal Subunit
Antigen Vaccine System
Raj K. S. Badhan 1 ID , Swapnil Khadke 2 and Yvonne Perrie 2,*
1 Aston Pharmacy School, School of Life and Health Sciences, Aston University, Birmingham B4 7ET, UK;
r.k.s.badhan@aston.ac.uk
2 Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK;
swapnil.khadke@strath.ac.uk
* Correspondence: yvonne.perrie@strath.ac.uk; Tel.: +44-414-548-2244
Received: 16 October 2017; Accepted: 4 December 2017; Published: 7 December 2017
Abstract: The pharmacokinetics of a liposomal subunit antigen vaccine system composed of the
cationic lipid dimethyldioctadecylammonium bromide (DDA) and the immunostimulatory agent
trehalose 6,6-dibehenate (TDB) (8:1 molar ratio) combined with the Ag85B-ESAT-6 (H1) antigen
were modelled using mouse in-vivo data. Compartment modelling and physiologically based
pharmacokinetics (PBPK) were used to predict the administration site (muscle) and target site (lymph)
temporal concentration profiles and factors governing these. Initial estimates using compartmental
modelling established that quadriceps pharmacokinetics for the liposome demonstrated a long
half-life (22.6 days) compared to the associated antigen (2.62 days). A mouse minimal-PBPK model
was developed and successfully predicted quadriceps liposome and antigen pharmacokinetics.
Predictions for the popliteal lymph node (PLN) aligned well at earlier time-points. A local sensitivity
analysis highlighted that the predicted AUCmuscle was sensitive to the antigen degradation constant
kdeg (resulting in a 3-log change) more so than the fraction escaping the quadriceps (fe) (resulting in a
10-fold change), and the predicted AUCPLN was highly sensitive to fe. A global sensitivity analysis of
the antigen in the muscle demonstrated that model predictions were within the 50th percentile for
predictions and showed acceptable fits. To further translate in-vitro data previously generated by
our group, the mouse minimal-PBPK model was extrapolated to humans and predictions made for
antigen pharmacokinetics in muscle and PLN. Global analysis demonstrated that both kdeg and fe
had a minimal impact on the resulting simulations in the muscle but a greater impact in the PLN.
In summary, this study has predicted the in-vivo fate of DDA:TDB:H1 in humans and demonstrated
the roles that formulation degradation and fraction escaping the depot site can play upon the overall
depot effect within the site of administration.
Keywords: pharmacokinetics; physiologically based pharmacokinetics; liposome; antigen;
adjuvant; vaccine
1. Introduction
The liposomal system composed of the cationic lipid dimethyldioctadecylammonium (DDA)
and the immunomodulating glycolipid trehalose dibehenate (TDB) is a two-component adjuvant
system known as CAF01. The CAF01 system has been shown to be effective in producing protective
immune responses against pathogens such as chlamydia, malaria, influenza and tuberculosis (TB) [1,2].
Korsholm et al. (2007) described that one of the key mechanisms behind this immunomodulatory effect
results from the cationic charge of the vesicles, which electrostatically binds and enhances antigen
uptake by antigen-presenting cells via actin-dependent endocytosis [3]. This action works in synergy
Pharmaceutics 2017, 9, 57; doi:10.3390/pharmaceutics9040057 www.mdpi.com/journal/pharmaceutics
Pharmaceutics 2017, 9, 57 2 of 15
with the immunostimulation provided by TDB; TDB is a synthetic analog of trehalose 6-6-dimycolate,
an immunostimulatory component of Mycobacterium tuberculosis, a mincle-recognised ligand and its
adjuvant effect in vivo is MyD88 dependent [4].
When considering the biodistribution of these cationic liposomal adjuvants after immunisation,
research from our group has shown that DDA:TDB liposomes are retained at the injection site and
that these vesicles promote the retention of antigen at the site of injection, thus promoting co-delivery
of both liposomal adjuvant and antigen to appropriate antigen-presenting cells [5]. A stable and
reproducible dual-radiolabelling method (whereby the adjuvant (liposome) is labelled with 3H and the
antigen (a subunit protein) with 125I) was used to track liposomes and antigen in vivo [6]. The depot
effect was found to be dependent on the cationic nature of vesicles; when DDA was replaced with
neutral lipid disteoryl phosphatidylcholine (DSPC), no depot was formed at site of injection and lower
levels of immune responses were noted [7]. It has also been shown that DDA:TDB vesicles from ~200 to
1500 nm have similar clearance kinetics from the injection site. This suggests that with these cationic
systems, size reduction does not modify clearance kinetics [8]. This could be a result of aggregation
of these cationic liposomes after injection. Furthermore, whilst not modifying the clearance rates of
the vesicles, the presence of TDB within the liposomes promotes increased recruitment of monocytes
to the depot, again demonstrating the synergistic delivery and stimulatory action of the DDA:TDB
formulation [5]. However, clearance rates from the injection site can be increased by PEGylation
of these cationic liposomes [9,10]. Due to the hydrophilic chains of the polyethylene glycol (PEG)
extending out from the surface of the liposomes, the cationic charge of the DDA is masked and hence
aggregation is blocked [9]. This results in a faster drainage of the liposomes from the site of injection
compared to non-PEGylated liposomes [9,10].
Despite these recognised links between distribution profiles and vaccine efficacy, the application
of pharmacokinetic modelling and simulation to vaccines is sparse. This often results from a lack
of understanding of how traditional pharmacokinetic terms developed for low molecular weight
agents can be correlated to antigen dose, safety and efficacy, and is supported by a lack of appropriate
correlations to efficacy. A complete understanding of the pharmacokinetics of liposomal formulations
is limited, and modelling approaches to support formulation development is still in its infancy as
a discipline. However, recently, a number of groups have begun to develop mechanisms by which
to understand these processes in the context of pharmacokinetic modelling and simulation [11–17].
Whilst the pharmacokinetics of the Ag85B-ESAT antigen has not been assessed in humans, a liposome
formulation with the antigen has undergone phase-1 trials demonstrating safety and tolerability [18,19].
The purpose of this study was to explore the potential to apply the principles of pharmacokinetic
modelling and simulation to the analysis of the kinetics of liposome–antigen disposition data generated
in mice through traditional compartmental modelling and physiologically based pharmacokinetics
(in humans).
2. Materials and Methods
2.1. Data Collection
Data previously generated by our group from a dual radio-labelled DDA:TDB liposome–adjuvant
(Ag85B-ESAT-6) formulation [9,20–22] was used for these pharmacokinetics studies. Biodistribution
data obtained from these previous studies was used as either relative to the percent dosed or converted
to mass units (300 µg liposome and 2 µg antigen) for dosing. During these studies from which the
data was used, radio-labelled antigen and liposomes were used as previously outlined [6]. Briefly,
the antigen was radio-labelled with 125I using Pierce iodination tubes containing Pierce iodination
reagent. The tubes contain an oxidizing reagent which converts NaI into a reactive iodine molecule
that can insert into the tyrosol group of tyrosine amino acids. Liposomes were radio-labelled using
commercially available tritiated lipid dipalmitoyl phosphatidylcholine (DPPC). Addition of this
tracer lipid did not affect the physicochemical properties of DDA:TDB. Liposome membrane stability
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and retention of the radiolabel tracer upon exposure of liposomes to the in-vivo environment was
previously confirmed using stability studies at 37 ◦C in a high-protein environment (50% Fetal
Calf Serum (FCS)) [5]. Mice were injected with Ag85BESAT-6 (radiolabeled with 125I)-adsorbing
liposome (radiolabeled with 3H) formulations (50 µL/dose, im (intramuscular) injection). At 1, 4 and
14 days post-injection (pi), mice were terminated by cervical dislocation and tissue from the site of
injection (SOI), and local draining lymph nodes (LNs) were removed for analysis of liposome (3H) and
antigen (125I) using methods previously described elsewhere [6].
In the studies where the in-vivo data were used in the modelling, liposomes were composed of
DDA:TDB at a weight ratio of 5:1. Mice received 50 µL/dose which contained 250 µg DDA, 50 µg TDB
and 2 µg of antigen. Liposomes were in the range of 400 to 600 nm in size (z-average diameter of
481 ± 20 with a PDI of 0.23 ± 0.1) and highly cationic in nature (55 to 65 mV).
2.2. Compartmental Modelling of Data
A 1-, 2- and 3-compartment model (Figure 1) was used to fit the data for the liposome and antigen to
model the kinetics at the site of administration (central compartment). Differential equations described
a 1-, 2- and 3-compartment model and were numerically solved using Matlab (The MathWorks Inc.,
Natick, MA, USA, 2015):
1-compartment model:
dC1
dt
= −k10·C1; (1)
2-compartment model:
dC1
dt
= −(k10 + k12)·C1 + k21·C2; (2)
dC2
dt
= K12·C1− k21·C2; (3)
3-compartment model:
dC1
dt
= −(k10 + k12 + k13)·C1 + k21·C2 + k31·C3; (4)
dC2
dt
= K12·C1− k21·C2; (5)
dC3
dt
= K13·C1− k31·C3; (6)
where Cn: concentration in nth compartment; t: time; k10: elimination rate constant; k12: transfer rate
constant from central (1) to peripheral (2) compartment; k21: transfer rate constant from peripheral (2)
to central (1) compartment; k13: transfer rate constant from central (1) to peripheral (3) compartment;
k31: transfer rate constant from peripheral (3) to central (1) compartment.
Pharmacokinetics parameters were then calculated based on the best-fitting model selected
according to the Akaike information criterion (AIC).
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Figure 1. Schematic diagram of compartmental model. Boxes represent non-physiological 
compartments within which the drug is capable of distributing. Arrows indicate direction of transfer 
between compartments with ‘k’ indicating a transfer rate constant and the numerals indicating the 
direction of transport. k10 reflects degradation from a compartment. 
Figure 1. Schematic diagram of compartmental model. Boxes represent non-physiological
compartments within which the drug is capable of distributing. Arrows indicate direction of transfer
between compartments with ‘k’ indicating a transfer rate constant and the numerals indicating the
direction of transport. k10 reflects degradation from a compartment.
2.3. Mechanistic Modelling of Data
Minimal-PBPK (physiologically based pharmacokinetics) models of mice (28 g) and humans
(71 kg) [23] were developed and accounted for the site of injection (muscles), target site (PLN), rest of
body (ROB) and plasma (Figure 2). Compartments were assigned physiological volume parameters
and connected through physiological flows (Table 1). A more mechanistic model, with the inclusion
of, for example, a tissue partition coefficient, was not developed due to the lack of rich sampling data
points to develop/validate the model with.
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Table 1. Anatomic and physiological parameters used in the physiologically based pharmacokinetics
(PBPK) models; PLN: popliteal lymph node 1.
Compartment Flow (L/Day)Symbol Mouse Human
Volume (L)
Symbol Mouse Human
Plasma Qplasma - - Vplasma 9.44 × 10−4 [24] 3.13
Quadriceps Qmuscle 2.60 [24] 32.04 [25] Vmuscle 1.6 × 10−4 [26] 0.19 [25]
PLN QPLN 2 × 10−3 [27] 0.52 [27] VPLN 5 × 10−6 [26] 3.5 × 10−3 [27]
Rest of Body Qrest 18.10 3.02 × 104 Vrest 2.6 × 10−2 67.68
1 Except where indicated, all parameters were taken from [23].
The following assumptions were made for this model:
• All tissues were modelled based on the total tissue volume (derived from tissue mass), and,
where necessary, assuming a density of 1.
• The ‘muscle’ compartment was modeled solely by the quadriceps tissue component in mice and
the deltoid tissue in humans.
• The ‘lymph’ compartment was modelled solely by the popliteal lymph node (PLN) with an
estimated whole tissue volume of 0.05 mL [28] (assuming a density = 1) in mice. In humans we
assumed a mass of 0.05 g/kg body weight, based on a similar relationship in rabbits [27].
• Plasma flow to and drainage from the PLN were assumed to be 0.012% cardiac output [27].
• The fraction escaping (fe) the quadriceps and being drained into the PLN was fixed at 3 × 10−5
for liposome and 3.6 × 10−6 for antigen, to reflect fraction escaping the muscle based upon the
average ratio of percent accumulation for all time points in the target tissues compared to the
dose administered. The small-pore theory of molecular translocation across a membrane would
preclude molecules below 60 nm in size from undergoing transvascular flow across a capillary
wall [29–32].
• Dosing was modelled as a rapid first-order dose into the quadriceps (approximating a bolus dose)
with a ka = 10 day−1. The human model focused on simulating antigen only and therefore a
human dose of 50 µg was modelled.
• In the absence of plasma concentration of both liposome and antigen and the limited muscle and
PLN biodistribution data, an attempt to estimate an appropriate tissue partition coefficient was
not conducted and transfer of liposome/antigen out of the site of administration was assumed
to occur only through exiting via the muscle blood flow (accounting for the fraction escaping)
and the transfer via lymphatics. Transvascular flow was therefore modelled as a rate constant
(when accounting for tissue volume):
tvtissue =
Qtissue
Vtissue
fe.
Differential equations describing the drug flow in the model were solved in Matlab
(The MathWorks Inc., Natick, MA, USA, 2015) and are detailed as follows:
Plasma:
Vplasma·
dAplasma
dt
= −(∑Qtissue)·Cplasma + (Qrest·Crest) + (tvmuscle·Cmuscle) +
(
tvlymph·CPLN
)
. (7)
ROB:
Vrest·dArestdt = −
(
(Qrest·Crest) +
(
kdeg,rest·Crest
))
+
(
Qrest·Cplasma
)
. (8)
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Quadriceps:
Vmuscle·dAmuscledt = ka·Dose− ((tvmuscle·Cmuscle ) +
(
kdeg,muscle·Cmuscle
)
+(
tvlymph·Cmuscle
))
+
(
Qmuscle·Cplasma
)
.
(9)
PLN:
VPLN·dAPLNdt = −
((
tvlymph·CPLN
)
+
(
kdeg,PLN·CPLN
))
+
(
QPLN·Cplasma
)
+(
tvlymph·Cmuscle
)
.
(10)
Given the lack of robust plasma and whole-body temporal concentration data, parameter
optimisation was initially avoided as far as possible, except for the optimisation of the degradation
rate constant of the formulation from each tissue (kdeg,tissue). Optimisation was conducted using a
non-linear least-squares fitting algorithm based on previously reported data. Final model simulations
were confirmed through visual inspection and observed versus predicted plots (for mouse model only).
The percent predictive error (PE) was calculated (see Equation (11)) for mouse data only, where Cpred
is the model-predicted concentration and Cobs the observed concentration:
% PE =
Cpred −Cobs
Cobs
× 100%. (11)
2.4. Parameter Sensitivity Analysis
An uncertainty analysis was performed to determine how variations in model parameters would
influence the depot effect in the target site (muscle) for the mouse model only. A local analysis was
performed on Qmuscle, kdeg and fe, and was scanned over a defined range (Qmuscle: ±3-log; kdeg: ±3-log
and fe: ±4-log). 3D surface plots of the relationship between two input parameters and the AUCmuscle
were compared in the muscle and the PLN.
A global analysis was also conducted on muscle kinetics for the liposome and antigen,
with scanning limits set as detailed above. Monte Carlo simulations with 1000 simulations were
performed with the Latin hypercube sampling algorithm for both the mouse and human models.
The resultant 50th and 95th percentiles were graphically assessed.
3. Results
3.1. Compartment Modelling
The pharmacokinetics of the liposome formulation was best described by a 1-compartment model
with antigen described by a 2-compartment model (Figure 3). Antigen stability was described by fitting
in-vitro stability data to a bi-exponential first-order degradation model (Figure 4), demonstrating a
terminal half-life of 2.62 days and relatively slow degradation rate of 0.34 day−1 (Table 2).
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Table 2. Summary of model-fitted pharmacokinetic parameters.
Liposome
K10 0.0306 day−1
t1/2 22.6 days
MRT 32.6 days
AIC 49.54
Antigen
k10 0.34 day−1
k12 22.26 day−1
k21 77.58 day−1
t1/2α 0.0069 day
t1/2β 2.62 days
MRT 3.78 days
AIC 37.4
Parameters best fit a 1-compartment model for the liposome and a 2-compartment model for the antigen. MRT: mean
residence time; t1/2α: distribution half-life; t1/2β: terminal half-life; AIC: Akaike information criterion.
3.2. Minimal-PBPK Models
We first aimed at developing a physiological model which best mimicked the kinetics of
distributional transfer and degradation kinetics of the formulation at the key target site, namely the
muscle. This was further followed on by assessing the ability to predict drainage of the formulation into
the local lymph node, that is, the PLN. Modelling was generally deemed to be successful, particularly for
the muscle and for both the liposome and antigen. The PBPK model developed was able to capture the
kinetics within the compartment with a PE < 33% for the liposome (Figure 5A,B and Table 3). For the
antigen, the precision PE was less than 14% for time points 1–4 days, with the final time point showing
a larger error (65.9%) (Figure 5C,D and Table 2). In a similar fashion the PLN predictions were also
generally successful but demonstrated poorer predictions at 14 days. Fitting of the degradation rate
constants yielded estimates that were similar to those from compartment modelling and in-vitro data
(Table 4), with antigen demonstrating on average a 10-fold higher rate constant than liposomes.
Table 3. Precision error calculations.
Time (Days)
% Precision Error
Muscle PLN
Liposome Antigen Liposome Antigen
0.25 16.4 13.5 - -
1 32.7 5.3 28.4 32.7
4 3.9 13.8 13.90 41.5
14 3.8 65.9 66.3 74.0
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Table 4. Parameter estimates for kdeg.
Compartment
Degradation Constant (Day−1 ± SD)
Symbol Liposome Antigen
Plasma - - -
Quadriceps kdeg,muscle 0.051 ± 0.008 0.320 ± 0.028
PLN kdeg,pln 0.132 ± 0.004 0.280 ± 0.013
Rest of Body kdeg,rest 0.091 ± 0.040 0.110 ± 0.030
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3.3. Sensitivity Analysis
In light of sparse observed ata sets, the tivity of model input parameters was evaluated
through both global and local sensitivity analyses. cal sensitivity analysis was conducted on kdeg,
fe, Qmuscle and Qlymph, where the impact of two of these parameters on AUCtissue was assessed.
Analysis was conducted with both liposomes and antigen, with similar trends in sensitivities and
therefore liposome trends reported in Figure 6.
The analysis revealed that the AUCmuscle was most sensitive to kdeg,muscle (Figure 6A), leading to
a 2-log magnitude change in AUCmuscle over the kdeg,muscle range studied (0.001–10 day−1), and more
particularly beyond 0.1 day−1. Our model-fitted estimate for kdeg,muscle was at the lower end of this
sensitivity. AUCmuscle was also highly sensitive to changes in fe, with Qmuscle not impacting upon the
sensitivity of AUCmuscle (Figure 6B).
AUCPLN was most sensitive to changes in fe, with an almost 8-log-order change in AUClymph
over the range of fe studied (Figure 6C). Qlymph and kdeg,pln also resulted in some level of sensitivity on
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AUClymph (Figure 6C), however, our estimates for kdeg,pln are at the upper limit of the sensitivity of the
parameters towards AUC and Qlymph in the mid-range, but in both cases a 50% change in parameter
would still provide an estimate of AUClymph within the same order of magnitude (Figure 6D).
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As a result of these local simulations, kdeg,muscle and fe were selected for global analysis in the
muscle for the antigen (Figure 7). The global analysis revealed a limited uncertainty in the predictions at
the earlier time-points for kdeg,muscle (Figure 7A), with the uncertainty increasing later in the simulation.
With fe, sensitivity analysis revealed no impact on predictions with very low fe (<1 × 10−5) (Figure 7B),
but when fe was increased above 1 × 10−5, the uncertainty around the Cmax increased significantly
(Figure 7C) and impacted more on the earlier time points (<6 days).
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3.4. Human Model
The mouse model was extrapolated to develop a human PBPK model for the antigen only with the
dose adjusted to reflect a single dose administered in adults (i.e., 50 µg). In the muscle, the predicted
Cmax was 0.25 µg/mL with a tmax of 0.5 days and half-life of 13.2 days (Figure 8A,B). In the PLN the
predicted Cmax was 0.0438 pg/mL with a tmax of 2 days and half-life of 13.2 days (Figure 8C,D). A global
sensitivity analysis was then conducted to compare kdeg,tissue and fe on muscle and PLN concentration.
Uncertainty in the predictions on antigen concertation in the muscle with variation of kdeg (±50%)
was minimal at the earlier time point, but became more uncertain during the simulations (Figure 8A).
For variations in fe, the antigen concentration in the muscle was not sensitive to any change over the
range of 1e−8 to 1e−5 (Figure 8B-insert). However, for the range of 1 × 10−5 to 1 × 10−1, muscle antigen
concentration demonstrated minimal sensitivity and predictions were within the upper 95th percentile
(Figure 8B). For the PLN, this uncertainly was significantly greater and predictions were within the
lower 95th percentile range for both kdeg (Figure 8C) and fe (Figure 8D).
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4. Discussion
Vaccination plays a key role in the protection of life and promotion of global public health. The use
of liposomal vaccine adjuvants offers new approaches to take advantage of the immunomodulatory
properties imparted by these systems. This study has focused on demonstrating how mathematical
modelling, in the form of pharmacokinetics modelling and simulation, can be applied to gain an early
perception of the pharmacokinetic properties of formulation systems for vaccines and adjuvants.
4.1. Compartmental Modelling
Compartmental modelling is a widely used empirical tool which can be used to quantify the
pharmacokinetics of a molecule of interest from existing data. It makes the assumption that drug
distributes instantaneously within a compartment and that the central compartment is often assumed
to be the dosing or ‘plasma’ compartment. Compartment modelling in this context models the kinetics
within the dosing (quadriceps muscle) compartment in an attempt to describe the pharmacokinetics of
both the liposome and the associated antigen.
Compartment modelling demonstrated that the liposome is indeed relatively stable and resides
at the site of injection. The antigen on the other hand yielded a 10-fold higher elimination rate
(k10) compared to the liposome (Table 2). As k10 is traditionally viewed as an ‘elimination’ process,
in this context it can be related to processes driving the reduction of liposome from the dosing
compartment. The higher k10 for antigen may suggest either a more-rapid degradation process
within the muscle tissue or more-rapid transfer out of the injection site. A significant drawback of
compartmental modelling is highlighted in this approach, as it is difficult to assign biochemical or
physiological processes to the rate constants that define the compartmental transfer of the formulation.
This can include uptake by antigen-presenting cells, which will take up and clear the vaccine from the
injection site. Our analysis of the reported in-vitro stability of antigen demonstrates that the antigen
was relatively stable in vitro (in the absence of enzymatic degradation processes), with a degradation
rate of 0.01 day−1. This demonstrates a relatively slow degradation process and leads to a long terminal
half-life of approximately 60 days. A key drawback of compartmental modelling is the inability to
extrapolate to other species (e.g., humans) and other types of formulations as the very structure of the
model is intricately tied up, and its empirical nature requires in-vivo data to model.
4.2. Physiological Modelling
Physiologically based pharmacokinetics (PBPK) is an adaptation of compartmental modelling,
where the system is described in the context of physiological and biochemical properties, that is,
tissue volumes, blood flows and protein/enzymatic expression. We opted to develop a minimal-PBPK
model; a model that is semi-physiological and which accounts for the key processes governing
formulation disposition at the site of administration and target tissues. Our rationale for choosing
this approach, as opposed to a full implementation of a whole-body PBPK model, was driven by:
(i) the sparse data available from existing studies for our formulation of choice; (ii) the lack of plasma
data which is important when developing a whole-body PBPK model; and (iii) the desire to avoid
fitting a large majority of model parameters where the final estimates would undoubtedly be unreliable
due to the limited available data.
Our approach developed four compartmental models consisting of blood, rest of body, muscle
and popliteal lymph node (PLN) sites (Figure 2), with the site of administration being the muscle.
Parameter estimation was only conducted for the degradation of liposomes or antigen at each tissue site.
The initial model estimates of the liposomes in the muscle were relatively good, with the exception
of the fit at day one (PE = 32.7%), with a similar trend for the liposome in the PLN, with good fits to
observed data except for day 14 (PE = 66.3%) (Table 2). The large variability in the 0.25-day observed
sampling point and poorer fit at day one may suggest non-uniform tissue distribution following im
injection. However, the lack of plasma data precluded further analysis of this to ascertain why there is
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this mismatch. In a similar fashion, the poor fit at days 14 in the PLN would suggest an alternative
competing process resulting in the slower penetration into the tissue (Figure 5A). Yet, given the limited
data points, this first approach at modelling the kinetics of liposome distribution from muscle into
PLN is relatively successful. Indeed, the dose reaching the blood was significantly lower (<1 × 10−6%
of the administered dose) and highlights the expected depot effect the muscle provides in maintaining
the formulation within the dosing tissue.
For the antigen, we were able to describe the muscle kinetics relatively well with a higher PE at
days 14 (65.9%) (Figure 5A and Table 2). Our model prediction for the PLN was predominately within
the same order as magnitude as the reported data but with a higher PE than the muscle compartment.
Given these concerns, we conducted a local sensitivity analysis to better identify parameters that lead
to sensitivity to the residence of drug within the muscle and PLN (Figure 6). Both kdeg,muscle and
fe resulted in sensitivity towards AUCmuscle (Figure 6A), with kdeg,muscle being the most sensitive to
changes in AUCmuscle. This suggests that fe only plays a minor role in governing the residency of
the formulation within the muscle. For example, an 8-fold log change in fe at a fixed kdeg,muscle of
0.051 day−1 resulted in 2-fold change in AUCmuscle (Figure 6A), whereas a fixed fe utilised within the
model resulted in a 3-log change in AUCmuscle over the range of kdeg,muscle simulated.
In the PLN, both fe and kdeg,pln were able to affect AUC, with changes in fe again being more
prominent in influencing AUCPLN (Figure 6C,D). At a fe = 1, AUCPLN is less sensitive to changes in
kdeg,pln (Figure 6C), presumably as a result of the unhindered formulation flux between compartments.
However, when fixed at 1 × 10−8, kdeg,pln resulted in a 5-fold change in AUCPLN and became more
important in controlling AUCPLN.
The local analysis has revealed the need to further quantify the ‘degradation’ process (i.e., antigen
processing pathways: update, degradation, complex formation and presentation) to improve the
sensitivity of the model to changes (estimates) for kdeg,tissue and fe. A more mechanistic approach
to describe these pathways may better capture the kinetics events associated with kdeg,tissue. In particular,
when considering a global sensitivity analysis (Figure 7), with respect to the impact of both kdeg,muscle
(Figure 7A) and fe (Figure 7B) on percent dose, our predictions are within the 50th and 95th percentile
in the muscle, but there is more uncertainty in the PLN, where a significantly wider range for the 95th
percentile exists. This, coupled with the relatively low recovery, may require further studies to better
characterise the reasons for such low accumulation (if it cannot be attributed to the size and impact on fe).
When extrapolating our model to humans, we have obtained first estimates of the potential
injection site concentration (Figure 8) with a predicted mean Cmax of 0.25 µg/mL and long half-life of
13.2 days in the deltoid muscle. This half-life is shorter than that predicted in the mouse quadriceps.
The degradation of the antigen appears to have a more prominent role in governing its residency
within the muscle (Figure 8A) rather than its ability to be cleared from the muscle tissue (Figure 8B).
This may reflect the size of the liposomes (approximately 500 nm and highly cationic in nature) and
their ability to be cleared from the depot site. Our approach to utilise percent-recovery data is a suitable
first approximation at determining a static true ‘in-vivo’ parameter, particularly as the size of the
nanoparticle would be expected to significantly hinder its drainage from the deport into the PLN and
hence, our first-principals approach is justified.
In summary, this study has demonstrated the potential to apply the principles of pharmacokinetics
to assess in-vivo data from liposome studies, but also shows how we can apply pharmacokinetics in
a mechanistic approach to allow cross-species extrapolation. It must be noted that caveats exist and
should be considered when the reader wishes to apply pharmacokinetics principles to data sets.
Lack of plasma data: Key to any pharmacokinetics study is the requirement to sample from the
blood/plasma. By sampling from the plasma (in addition to the target site), the reader is then able to
take account of distributional processes to other tissues and hence move the model towards a more
mechanistic full-PBPK model rather than the semi-mechanistic PBPK model presented in this study.
Interpretation of tissue partition: The passage of a therapeutic entity through a cell requires
partitioning across cellular membranes. This is often accounted for by the tissue partition coefficient
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(kp) [33,34], which can readily be predicted from the physiochemical properties of low molecular
weight compounds. Our approach did not address this issue and assumed there was no inherent
permeability barrier, with transvascular flux being the main factor governing the entry/exit to a tissue.
Possessing prior knowledge of the formulation system, we surmised that the liposomes would be
unable to partition out due to their size (~500 nm) and hence have focused on the depot effect provided
by the muscle. For other nanoparticles, this may not be the case, and kps would need to be determined.
By possessing plasma data along with some additional tissue data, it would be possible to obtain first
estimates of the kp for each tissue of interest.
Modelling antigen pharmacokinetics: Our approach to the pharmacokinetic modelling of the
antigen element of the formulation is simplistic when considering the multitude of processes involved
in the absorption, distribution, metabolism and elimination (ADME) processing of the antigen, along
with non-linear processes such as FcRn-mediated transcytosis and target site-mediated processes.
A driving force for the selection of an appropriate model is the availability of data that support model
development, and in this case we have presented a first-principles approach to capture some elements
of the antigen pharmacokinetics.
5. Conclusions
In conclusion, this study showed an approach for predicting the in-vivo fate of DDA:TDB:H1 in
humans and demonstrated the role that formulation degradation and fraction escaping the depot site
can play in the overall depot effect within the site of administration.
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